Chad Link, DO
Cardiovascular Disease · Lansing, MINPI 1750504585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $278,243 of the $315,431 with a category attached, or 88.2%. 34 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 35.5% of the total. Reporting peaked in 2019 at $61,486 and has fallen 61.6% since, to $23,599 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 705 payments — averaging $447.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$112K
- AstraZeneca$52K
- Pfizer$45K
- Boehringer Ingelheim$37K
- Kiniksa Pharmaceuticals International, PLC$20K
- Lilly USA, LLC$16K
- plus $34K from 28 others
Across 108 payments — averaging $1697.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$62K
- Janssen Research & Development, LLC$43K
- Boehringer Ingelheim International GmbH$42K
- Boehringer Ingelheim Pharma GmbH & Co.kg$13K
- Actelion Pharmaceuticals, Ltd$11K
- Merck$9K
- plus $3K from 2 others
What the payments were for
- Consulting fees$15,0675%
- Speaking & faculty fees$278,24388%
- Travel & lodging$8,9153%
- Food & beverage$12,8464%
- Education$3610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 130 | $111,853 |
| AstraZeneca(2 entities) | 88 | $51,717 |
| Pfizer | 72 | $45,485 |
| Boehringer Ingelheim | 69 | $36,847 |
| Kiniksa Pharmaceuticals International, PLC | 21 | $20,116 |
| Lilly USA, LLC | 16 | $15,558 |
| E.r. Squibb & Sons, L.L.C. | 39 | $13,049 |
| Sanofi-aventis U.S. LLC | 27 | $9,946 |
| Johnson & Johnson(2 entities) | 32 | $4,958 |
| Boston Scientific | 33 | $888 |
| Novartis | 41 | $761 |
| Bristol Myers Squibb | 1 | $600 |
| Amgen | 29 | $488 |
| Bayer | 19 | $386 |
| Medtronic | 5 | $324 |
| Abiomed | 3 | $324 |
| Amarin Pharma, Inc. | 14 | $255 |
| United Therapeutics Corporation | 11 | $253 |
| Inspire Medical Systems, Inc. | 4 | $244 |
| Astellas Pharma US Inc | 4 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $167 |
| Alnylam Pharmaceuticals Inc. | 5 | $160 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $124 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Esperion Therapeutics, Inc. | 2 | $111 |
| Abbott | 1 | $109 |
| Edwards Lifesciences | 1 | $99 |
| Teleflex LLC | 1 | $92 |
| Merck | 5 | $92 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $12 |
| Janssen Scientific Affairs, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$95,945
- OPSUMIT$89,275
- JARDIANCE$51,420
- FARXIGA$47,855
- ELIQUIS$42,794
- ARCALYST$19,749
- VYNDAQEL$10,251
- MULTAQ$4,200
- DISEASE STATE$3,393
- LOKELMA$2,407
- VELETRI$545
- Impella$233
- ENTRESTO$123
- Peripheral Orbital Atherectomy System$120
- Coronary Orbital Atherectomy System$120
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
How this compares
$315,431 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 59 | $1,597,156 |
| OpsumitMacitentan | 115 | $1,442,962 |
| EliquisApixaban | 463 | $582,288 |
| JardianceEmpagliflozin | 169 | $197,391 |
| EntrestoSacubitril/Valsartan | 154 | $163,557 |
| Repatha SureclickEvolocumab | 205 | $140,138 |
| FarxigaDapagliflozin Propanediol | 78 | $88,131 |
| XareltoRivaroxaban | 68 | $83,116 |
| Praluent PenAlirocumab | 31 | $18,553 |
| Repatha SyringeEvolocumab | 21 | $12,353 |
| Rosuvastatin Calcium | 425 | $10,436 |
| Icosapent Ethyl | 35 | $10,287 |
| VascepaIcosapent Ethyl | 18 | $9,389 |
| Sildenafil Citrate | 51 | $8,802 |
| Ranolazine ErRanolazine | 57 | $6,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $111,853 | $3,040,117174 claims |
| PfizerEliquis | $45,485 | $582,288463 claims |
| Boehringer IngelheimJardiance | $36,847 | $197,391169 claims |
| NovartisEntresto | $761 | $163,557154 claims |
| AstraZenecaFarxiga | $51,717 | $88,13178 claims |
| Johnson & JohnsonXarelto | $4,958 | $83,11668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Lansing
- David StroblLansing$445K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.